Key Takeaways PHST001 targets CD24, a protein that helps tumors evade immune destruction, potentially enhancing immune response against cancer cells. The FDA's fast track designation accelerates the ...

Key Takeaways Pheast Therapeutics has begun a phase 1 trial for PHST001, targeting CD24 in advanced solid tumors, to evaluate safety and determine the phase 2 dose. PHST001 has shown promising ...

Dr. Rousseau to lead clinical development as Pheast advances PHST001, a novel anti-CD24 macrophage checkpoint inhibitor, into clinical trials February 18, 2025 09:00 AM Eastern Standard Time ...

Pheast Therapeutics Inc. has announced the presentation of preclinical data for PHST-001, a therapeutic monoclonal antibody targeting CD24, a macrophage checkpoint.